Compumedics secures approval for neuroimaging system for epilepsy and pre-surgical brain function mapping.
Medical device company Compumedics has received U.S. Food and Drug Administration approval for its brain activity-mapping neuroimaging technology, Orion LifeSpan™ Magnetoencephalography (MEG).
The 510(k) clearance greenlights the MEG single Dewar system that maps brain activity by recording magnetic fields that are generated by the brain’s natural electrical currents. Powered by the CURRY™ neuroimaging platform, Orion LifeSpan offers a dual-helmet system, enabling recordings for both adult and pediatric patients.
In addition, according to company information, the system is vibration-free and vacuum-cooled with zero-loss helium recycling. It also offers real-time video archiving and full cloud integration.
Based on a press statement, this technology, which sells for between $3-4 million, can primarily be applied in the clinical setting for epilepsy and pre-surgical brain function mapping. The Barrow Neurological Institute in Arizona has completed the first installation and first-phase commissioning of the system.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.